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Recombinant adeno-associated viral (rAAV) vectors are frequently used for gene delivery to the central nervous system and are capable of
transducing neurons and glia in vitro. In this study, seven serotypes of a rAAV vector expressing green fluorescent protein (GFP) were
characterized for tropism and toxicity in primary cortical cells derived from embryonic rat brain. At 2 days after transduction, serotypes 1 and 5
through 8 expressed GFP predominately in glia, but by 6 days post-transduction expression was neuronal except for AAV5. AAV2 and 9 produced
minimal GFP expression. Using cell viability assays, toxicity was observed at higher multiplicities of infection (MOI) for all serotypes except
AAV2 and 9. The toxicity of AAV1 and 5–8 affected mostly glia as indicated by a loss of glial-marker immunoreactivity. A frameshift mutation in
the GFP gene reduced overall toxicity for serotypes 1, 5 and 6, but not 7 and 8 suggesting that the toxicity was not solely due to the overexpression
of GFP. Collectively, a differential tropism and toxicity was observed among the AAV serotypes on primary cortical cultures with an overall
preferential glial transduction and toxicity.
Published by Elsevier Inc.Keywords: AAV; Adeno-associated virus; Gene therapy; Serotype; Tropism; Toxicity; Neuron; GliaIntroduction
Adeno-associated viral (AAV) vectors are a versatile platform
for gene delivery to the central nervous system (CNS) (Gao et al.,
2005; McCown, 2005; Tenenbaum et al., 2004; Xiao et al.,
1997). An AAV viral genome is approximately 4.7 kilobases
(kb) and contains two sets of viral genes, the rep and cap genes
important for replicating/packaging the viral DNA and produc-
ing the capsid proteins, respectively. The viral genes are flanked
by two 145 bp inverted terminal repeats (ITRs) which are re-
quired for replication and packaging. Recombinant AAV vectors
are most commonly generated by replacing all viral DNA be-
tween the ITRs with a transcriptional cassette of less than
approximately 5 kb. The resulting construct is cotransfected into⁎ Corresponding author. National Institute on Drug Abuse, National Institutes of
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doi:10.1016/j.virol.2007.10.007HEK293 cells with a plasmid containing helper virus genes and
rep/cap containing plasmid (Xiao et al., 1998). The resulting
rAAV lacks any viral genes and the serotype of the rAAV can be
altered by using different rep/cap constructs during packaging.
Currently, over 100 non-redundant genotypes of AAV have
been identified (Gao et al., 2005) and offer varied tropism. In the
rodent brain, Taymans et al. (2007) compared serotypes 1, 2, 5, 7
and 8 for tropism in various brain regions and found that these
serotypes were primarily neuronal (Taymans et al., 2007). Earlier
studies also found neuronal expression by serotypes 1, 2, 5, 7 and
8 (Burger et al., 2004; Cearley and Wolfe, 2006; Davidson et al.,
2000; Harding et al., 2006; Paterna et al., 2004). Additional
expression was observed in ependymal cells by serotypes 4 and 5
(Davidson et al., 2000), astrocytes by serotypes 5–8 (Davidson
et al., 2000; Harding et al., 2006), microglia by serotypes 2 and 5
(Cucchiarini et al., 2003) and oligodendrocytes by serotype 2
(Chen et al., 1999). In vitro studies using rAAV vectors have
identified transduced neurons (Cao et al., 2004; Garrity-Moses
et al., 2005; Keir et al., 1999; Kugler et al., 2003; Michel et al.,
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(Kugler et al., 2003; Nomoto et al., 2003; Shevtsova et al., 2005),
but these studies were conducted under different conditionsFig. 1. Serotype-specific expression of GFP in primary cortical cultures. Primary corti
days after transduction, cells were fixed and immunostained for NeuN (red; a–g)
transduced cells contained vacuoles of varying size (small and large arrows) devoid owith limited serotypes (2 and 5). No reports to date have com-
pared tropism of multiple serotypes on neurons and glia in vitro
under the same controlled conditions.cal cultures (DIV6) were transduced with different serotypes of dsAAVGFP. Two
or GFAP (red; h–n). Results from MOI=2×104. P) At 2×105 MOI, AAV1-
f GFP fluorescence (white) were observed. Scale bars: a–n) =50 μm, p) =25 μm.
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opportunity to conduct complex analysis of molecular mechan-
isms and cellular processes that would be impractical to test in
vivo initially. Neurons and glia grown in vitro are extensively
used to study the functions of genes and their proteins for
understanding basic mechanisms, modeling neurodegenerative
diseases and evaluating therapeutic potentials of genes and
compounds. One limitation to gene transfer studies in primary
neurons is the inefficiency and toxicity associated with trans-
fection methods (Jaworski et al., 2000; Martinez and Hollen-
beck, 2003; Watanabe et al., 1999). AAV vectors can efficiently
transduce primary neurons in vitro (see above) but the toxicity
of AAV vectors on primary neurons and glia in vitro has not
been well characterized.
One of the features that makes rAAV vectors a desired vector
for gene therapy in the brain is the low toxicity and im-
munogenicity. Delivery of rAAV2 vector to rodent brain pro-
duces minimal cellular immune response (Feng et al., 2004; Lo et
al., 1999; Mastakov et al., 2002). Lo et al. (1999) reported that
circulating antibodies to capsid, but not the transgene, were
detectable at 2–4 months after single injection of AAV, but
there was no correlation with antibody titers and transgene
expression. In a recent phase I clinical trial, a rAAV2 vector
delivered intraparenchymally showed no evidence of increased
neutralizing antibodies to AAV2 capsid in 7 of 10 patients and all
subjects showed minimal systemic signs of inflammation
or immune stimulation (McPhee et al., 2006). Although AAV
vectors have been used to transduce neurons and glia in vitro
(Cao et al., 2004; Garrity-Moses et al., 2005; Keir et al., 1999;
Kells et al., 2007; Kugler et al., 2003; Michel et al., 2005;
Nomoto et al., 2003; Shevtsova et al., 2005), there are no reports
examining the toxicity of different serotypes nor comparing
tropism under the same culture conditions. In addition to the
toxicity associated with the vector, the transgene can be re-
sponsible for toxic effects associated with viral vector trans-
duction. Previous studies have shown that overexpression of GFP
can be toxic to cells (Detrait et al., 2002; Klein et al., 2006; Liu et
al., 1999), therefore, it is important to differentiate the toxicity of
the transgene product from the vector/cell interactions.
The purpose of this study is to evaluate the tropism and
toxicity of seven serotypes (1, 2, and 5 through 9) of a double-
stranded rAAV vector expressing GFP in primary cultures
containing both glia and neurons. The vectors are packaged,
purified, titered and applied to primary cultures under the same
conditions. The toxicity related to the GFP transgene is also
examined by comparison to an AAV vector containing a frame-
shift mutation in the GFP gene (AAVΔGFP). Our results
indicate a differential expression of the GFP transgene (tropism)
and toxicity from AAV serotypes 1, 2 and 5 through 9 on pri-
mary neurons and glia in vitro. The pattern of toxicity and
tropism is consistent with the relatedness of the capsid proteins.Fig. 2. Loss of cell specific marker immunoreactivity in response to AAV serotypes.
with AAV serotypes on DIV6 and immunostained 6 days after transduction. Grap
immunoreactivity per field in the indicated AAV-treated group as percentage of the u
fields of (a) NeuN+ (red) or (b) GFAP-IR (red) and (a, b) GFP+ (green) cells for MO
Dunnett's post-hoc test;. Scale bar=100 um.Results
Tropism of AAV serotypes on primary cortical cultures
To broadly characterize the tropism of the various serotypes of
dsAAVGFP, primary cortical cultures were transduced on the 6th
day in vitro (DIV) at multiplicities of infection (MOIs) of 2×102,
2×103, 2×104 and 2×105 viral genomes (vg)/cell. At DIV8 or
DIV12 cultures were fixed and visualized after immunofluores-
cent amplification of GFP signal and immunolabeling neurons
(NeuN) or astrocytes (GFAP). Serotypes 2 and 9 exhibited
minimal GFP signal at the two highest MOIs tested on both DIV8
(Fig. 1) and DIV12 (Fig. 2) and showed 5–10% colocalization
with either GFAP-immunoreactive (IR) or NeuN-IR cells. Sero-
type 5 resulted in GFAP-IR and non-NeuN-IR cell expression of
GFP at DIV8 (Fig. 1). At DIV12, serotype 5 continued to show
colocalization to predominantly GFAP-IR and non-NeuN-IR
cells and the expression of GFAP appeared reduced (Fig. 2). On
DIV8 at each MOI, serotypes 1 and 6 exhibited the highest
intensity of GFP signal compared to all other serotypes which
were primarily colocalized to GFAP-IR cells and non-NeuN-IR
cells, but NeuN-IR cells expressing low GFP signal were present
at the two highest MOIs (Fig. 1a, d). Serotypes 7 and 8 produced
similar pattern of GFP expression as serotypes 1 and 6 but less
efficiently i.e. serotypes 1 and 6 at 2×104 was similar to 7 and 8 at
2×105 (Figs. 1 and 2). On DIV8 at higher MOIs, serotypes 1 and
6 produced GFP+ cells that were highly vacuolized suggesting a
cytopathic effect (Fig. 1p). At DIV12, the GFP expression in cells
transduced with serotypes 1, 6, 7 and 8 showed a high degree of
colocalization with NeuN-IR and a loss of colocalization with
GFAP-IR (Fig. 2a, b).
Effects of AAV serotypes on immunoreactivity of cell specific
markers
To determine whether the observed changes in the GFP
expression patterns from 2 to 6 days post-transduction were due
to loss of GFAP-IR, the cultures were examined at 2 and 6 days
after transduction for the presence of neurons (NeuN immuno-
reactive cells) or astrocytes (GFAP immunoreactivity). At
2 days post-transduction, there was no significant difference in
the number of NeuN-IR cells between non-transduced cells and
all serotypes tested at all MOIs (data not shown). Similarly, at
6 days post-transduction there was no change in NeuN+ cell
counts for all serotypes except AAV6 which exhibited a sig-
nificant decrease (pb0.05, One-way ANOVA–Dunnett's) com-
pared to non-transduced cells (Fig. 2a). At 6 days post-
transduction, cultures treated with serotypes 1, 6, 7 and 8 exhibit
GFP+ cells that mainly colocalize with NeuN-IR cells at the
higher MOIs, however AAV5 shows minimal colocalization
with NeuN (Fig. 2a panels).(a) NeuN or (b) GFAP immunoreactivity of primary cortical cultures transduced
hs (left) show the average number of (A) NeuN+ cells per field or (b) GFAP
ntreated group (dashed line) for different MOIs. Panels (right) are representative
I of 2×103, 2×104 and 2×105. #pb0.05 versus control by One-way ANOVA,
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Fig. 2 (continued ).
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significant difference among the serotypes and controls (data
not shown). At 6 days post-transduction, all serotypes showed
slight loss of GFAP-IR (15–20%) compared to controls at
nearly all MOIs (Fig. 2b). A MOI-dependent decrease in
GFAP-IR was observed at 6 days post-transduction for AAV1
and AAV6 (Fig. 2b). At the highest MOI (2×105), serotypes 5,
7 and 8 exhibited a further decrease in GFAP-IR compared
to the next lowest MOI, 2×104 (Fig. 2b). As observed at 2 days
post-transduction, AAV5 colocalized to GFAP-IR cells and
minimal expression was detected in NeuN-IR cells.(Fig. 2b).
Acute toxicity of AAV serotypes on primary cortical cultures
The acute toxicity associated with transduction by the various
serotypes was next examined as a function of MOI at 2 days
post-transduction. Primary cortical cultures were transduced on
DIV6 with various serotypes of dsAAVGFP at MOIs of 2×102,
2×103, 2×104 and 2×105 vg/cell. At 2 days post-transduction,
overall cell viability was assessed by lactate dehydrogenase
(LDH) release assay on the media and the bioreduction of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt (MTS) on cells. All serotypes
tested except 2 and 9 exhibited a MOI-dependent decline in cell
viability (Fig. 3a, b). At a MOI of 2×104, MTS levels were
significantly less in cultures treated with serotypes 1, 5, 6 and 7
compared to uninfected controls (pb0.05, One-way-ANOVA–
Dunnett's; Fig. 4a) Similarly, at a MOI of 2×104, LDH release
was significantly increased by serotype 1 (pb0.001, ANOVA–
SNK), 5 and 6 (pb0.05, ANOVA–SNK; Fig. 4c). Unlike the
MTS assay results at MOI of 2×104 (Fig. 4a) serotype 7 did not
show significant increase in toxicity over control by LDH assay
(Fig. 4c). Overall, serotype 1 exhibited the highest toxicity at all
MOIs. Serotypes 5 through 8 had less, but significant toxicity
compared to AAV1 and serotypes 2 and 9 had minimal toxic
effects.Fig. 3. Toxicity of AAV serotypes on primary cortical cultures. Primary cortical cultu
2 days later for viability. MTS assay (a) and LDH assay (b) of primary cortical cells a
2×104. #pb0.05 versus control by One-way ANOVA, Dunnett's post-hoc test; ⁎p
ANOVA, SNK post-hoc test.Mutating GFP partially attenuates toxicity of AAV serotypes on
primary cultures
To examine whether the observed toxicity was related to
toxic effects of GFP, a mutation was successfully introduced
into the GFP gene creating a frameshift after the 10th amino
acid of GFP that resulted in a protein (ΔGFP) that was 5 amino
acids longer than GFP but only homologous at the first 10 amino
acid. Primary cultures were transduced with the different
serotypes of dsAAVΔGFP at four MOIs. For all MOIs tested,
there was no detectable fluorescence from the dsAAVΔGFP.
Two days after transduction, the overall viability was assessed
by LDH release assay on the media and MTS assay on cells. At
2×104 MOI, dsAAVΔGFP serotypes 1, 5, 6, and 7 exhibited
significant decrease (approximately 10%, pb0.05, One-way
ANOVA, Dunnett's post-hoc), in viability by MTS compared to
untreated cells (Fig. 4a). However, there was no significant
difference compared to the serotype equivalent of dsAAVGFP at
the same MOI (Fig. 4a). Compared to untreated cells, no
significant change in LDH release was observed at 2×104 MOI
for all serotypes of dsAAVΔGFP, however, dsAAVGFP showed
significant increase in LDH levels for serotypes 1, 5 and 6
(Fig. 4c). At the highest MOI (2×105), dsAAVΔGFP exhibited
significantly less toxicity (pb0.05, t-test) than AAVGFP for
serotypes 1, 5, and 6 by both LDH and MTS assays. For
serotypes 7 and 8, both dsAAVGFP and dsAAVΔGFP caused a
significant decrease in cell viability compared to untreated cells
by both LDH and MTS assays (pb0.05, One-way ANOVA,
Dunnett's post-hoc), but there was no difference between
dsAAVGFP and dsAAVΔGFP by Student t-test (Fig. 4b, d).
Serotypes 2 and 9 of either dsAAVGFP or dsAAVΔGFP
produced no significant change in cell viability at 2×104 MOI
by MTS and LDH assay (Fig. 4a, c) or 2×105 by LDH assay
(Fig. 4d). There was a significant decrease in viability compared
to untreated cells by MTS assay at 2×105 MOI for serotypes 2
and 9 of dsAAVGFP (pb0.05, One-way ANOVA, Dunnett'sres (DIV6) were transduced with different serotypes of dsAAVGFP and assayed
nd media, respectively. Serotype comparison of MTS (a) and LDH (b) at MOI of
b0.05, ⁎⁎pb0.01 and ⁎⁎⁎pb0.001 versus adjacent lower MOI by One-way
Fig. 4. Effects of mutant GFP transgene on cellular toxicity. Primary cortical cultures (DIV6) were transduced with different serotypes of dsAAVGFP (solid bars)
or dsAAVΔGFP (hatched bars) at a MOI of 2×104 (a,c) and 2×105 (b,d). Two days after transduction, cell viability was measured by MTS assay (a,b) and LDH assay
(c,d). # pb0.05 versus control by One-way ANOVA, Dunnett's post-hoc test § pb0.05 Student t-test versus dsAAVΔGFP of same serotype.
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dsAAVGFP of the same serotype (pb0.05, Student t-test;
Fig. 4b).
Discussion
In this study the tropism and toxicity of AAV serotypes 1, 2,
5, 6, 7, 8 and 9 on primary cortical cultures derived from rat
embryos were examined. A double-stranded rAAV vector was
used to reduce the delay from viral exposure to transgene
expression by removing the requirement of the second-strand
DNA synthesis (Wang et al., 2003). In primary cortical cultures
transduced with dsAAVGFP, GFP expression could be detected
as early as 8 h after transduction using immunofluorescence to
amplify GFP fluorescent signal and at 2 days without ampli-
fication (data not shown). Using GFP fluorescence as an index
of tropism, at 2 days post-transduction there was a MOI-
dependent increase in GFP expression for all serotypes except
2 and 9. The use of GFP transgene expression for comparing
the tropism(s) of different serotypes of rAAVs has been
described (Burger et al., 2004; Cearley and Wolfe, 2006;
Paterna et al., 2004; Taymans et al., 2007). When examined
2 days post-transduction, the tropism (GFP expression) for all
serotypes was predominantly glia, however, by 6 days post-
transduction, the GFP expression was largely in NeuN-IR cells
at the higher MOIs. Previous studies have shown that AAV2 or
AAV5 containing the CMV promoter produced strongexpression in glia compared to neurons, but exchanging the
CMV promoter for the neuronal synapsin promoter restricted
the GFP expression to neurons (Kugler et al., 2003; Shevtsova
et al., 2005). In the current study, we examined the relative
differences among serotypes of GFP expression by the CMV
promoter and observed primarily glial expression initially
which changes to neuronal over time with the exception of
serotype 5.
The toxicity of the serotypes was characterized at 2 days post-
transduction using MTS and LDH assays which showed a MOI-
related toxicity for all serotypes except 2 and 9. Previous studies
have indicated that GFP overexpression has been linked to
neuronal toxicity (Detrait et al., 2002; Klein et al., 2006; Liu
et al., 1999). We found that, at the highest MOIs used for
serotypes 1 and 5 through 8, GFP expression was correlated with
LDH (R=.0.936; p=0.034). There is an inverse correlation
between GFP expression and MTS (R=0.8324; p=0.069). To
address whether the overexpression of GFP was contributing to
the overall toxicity, a frameshift mutation in the GFP gene of the
dsAAVvector wasmade to create amutant protein of similar size
but only the first 10 amino acids of GFP. At the highest MOI of
2×105, dsAAVΔGFP significantly reduced overall toxicity for
serotypes 1, 5 and 6, but did not affect the toxicity of 7 or 8. At
the next lowest MOI of 2×104, dsAAVΔGFP exhibited no
toxicity by LDH assay but similar toxicity to dsAAVGFP. To-
gether, the overexpression of GFP at the highest MOI is a large
contributor to the observed toxicity, but the differential effects
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isms of toxicity remain possiblymediated via viral vector protein
(s)–cell interactions. Although cells treatedwith AAV1 or AAV2
empty capsids with equivalent capsid proteins to those seen with
MOIs used above did not alter MTS or GFAP-IR compared to
untreated cells (data not shown). These data suggest that
serotype 1 toxicity is primarily due to the toxic effects of GFP,
but additional studies are needed to identify the toxic effects
observed with all serotypes tested.
The toxicity at the higher MOIs, particularly with serotypes 1
and 6, corresponds to an eventual loss of GFAP-IR. The GFP
expression in cells transduced with highest MOI of AAV1 or
AAV6 for 2 days reveals the presence of large intracellular
vacuoles in GFAP-IR cells. The vacuole may result from ex-
cessive endocytosis and accumulation of virion in multiple en-
dosomal pathways (Ding et al., 2005). Although the vacuoles are
likely clear predictors of cell death based on their early presence
in GFAP-IR cells and subsequent loss of GFAP-IR cells, the
exact mechanism by which they are formed and whether they
contribute to the cell death is not known.
When compared to the phylogenetic analysis of the capsid
viral protein 1 (VP1) for each serotype (Fig. 5), the intensity of
expression, cellular tropism and toxicity observations are con-
sistent with the relative capsid protein homologies. For exam-
ple, the pairs 1/6, 7/8 and 2/9 had similar characteristics in
tropism, expression and toxicity and each shows closest homo-
logy to each other. In fact, the homologies of AAV1 and AAV6
capsid proteins are nearly identical (Gao et al., 2002) and show
similar tropism and toxicity on the cortical cultures in the
current study. The toxicity of both serotypes 7 and 8 where
unaffected by mutating GFP and these two serotypes are closely
related. The parallels of serotype tropism, toxicity and capsid
homology imply that the observed differences in the serotypes
are a reflection of the capsid–cell interactions and are consistent
with observations that single amino acid changes can alter
tropism of AAV vectors (Wu et al., 2006). Cellular receptors
have been identified for serotypes 1 and 6 (sailic acid (Chen
et al., 2005; Seiler et al., 2006)), serotype 2 (heparan sulfate
proteoglycans (Summerford and Samulski, 1998)), fibroblast
growth factor 1 (Qing et al., 1999), integrin (Summerford et al.,
1999), hepatocyte growth factor receptor (Kashiwakura et al.,
2005) and laminin receptor (Akache et al., 2006), serotype 5
(platelet derived growth factor receptor (Di Pasquale et al.,
2003)), serotypes 8 and 9 (laminin (Akache et al., 2006)). ManyFig. 5. Phylogram of capsid proteins for AAV serotypes 1, 2 and 5 through 9. Tof these receptors are capable of signaling upon activation by a
ligand. AAV2 has been shown to promote pro-death pathways
in the absence of transgene expression (Duverger et al., 2002).
Future studies examining the capsid–receptor interactions for
the various serotypes may provide a better understanding of
how cell signaling and viability is altered by the process of
vector attachment and entry into the cell.
Based on the observations of this study, AAV vectors can be
toxic to cultured neurons and glia; therefore, a MOI at or below
2×104 vg/cell is recommended to create minimal toxicity to glia
and observable expression in both glia and neurons. This
recommended MOI is comparable to the MOIs (103 to 105) in
other in vitro studies using AAV-mediated gene transfer to
neurons (Cao et al., 2004; Doroudchi et al., 2005; Gong et al.,
2004; Kells et al., 2007; Kugler et al., 2003; Shevtsova et al.,
2005). To achieve further specificity and physiologically relevant
expression, the use of cell specific promoters will be needed. AAV
vectors have been generated to provide cell-restricted gene ex-
pression by virtue of a cellular promoter (Kugler et al., 2003;
Shevtsova et al., 2005). By incorporating cellular promoters into
select pseudotyped AAV vectors and transducing cells atMOIs of
minimal toxicity, the physiological or therapeutic levels of gene
product may be achieved in vitro.
Materials and methods
Primary cortical cultures
Cells were isolated from E15 embryos collected from timed-
pregnant Sprague–Dawley rats as described previously with
modifications (Cox et al., 2004) and in accordancewith approved
procedures by the NIH Animal Care and Usage Committee.
Specifically, brain cortices from E15 embryos were pooled and
digested 20 min in prewarmed (37 °C) 1 ml/embryo of 0.05%
trypsin–EDTA (0.2% (Invitrogen)). Cortices were triturated and
diluted in plating media [Neurobasal media (Invitrogen), 2%
heat-inactivated fetal bovine serum (Sigma-Aldrich, Milwaukee,
WI), 2%B27 supplement (Invitrogen), 200 mM L-glutamine and
25 mM L-glutamate] added at approximately 2 ml per embryo.
Viability was assessed by trypan blue staining (Invitrogen) and
cells were plated at 3×104 viable cells/well in 0.2 ml plating
media into 96 well plates coated with 0.15–0.2% polyethyle-
neimine in 150 mM sodium borate, pH 8.5 (Sigma-Aldrich).
Plated cells were placed in a 37°C humidified incubator withree rooted to AAV2. Units represent frequency of changes per 100 residues.
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day in vitro (DIV4) with feed media (plating media without
serum or glutamate).
Plasmids
The construction of pdsAAVGFP has been described pre-
viously (Wang et al., 2003). To generate pdsAAVΔGFP,
pdsAAVGFP was digested with BseRI and T4 polymerase to
remove the 3′ overhang of 2 bases. This created a frameshift
mutation at amino acid 11 of GFP and an overall protein of 243
amino acids (compared to 238 aa of GFP). For the serotypes 1, 2,
5, 6, 7, 8 and 9 the respective plasmids were used in transfections
described below: pXR1 (aka pXX12; (Rabinowitz et al., 2002)),
pXX2 (Xiao et al., 1998), pXR5 (Rabinowitz et al., 2002),
pAAV2/6 (Rutledge et al., 1998), pAAV7 (Gao et al., 2002),
pAAV8 (Gao et al., 2002), and pAAV9 (Gao et al., 2004).
Plasmids used for packaging AAV were generously provided by
Dr. Xiao Xiao (UNC, Chapel Hill, NC).
AAV packaging
All vectors were prepared by triple transfection method as
described (Xiao et al., 1998). Specifically, HEK293 cells are
grown in 293 media [DMEM-HG (Invitrogen)] containing 5%
bovine growth serum, (BGS; HyClone, Logan, UT) and 1%
penicillin–streptomycin in 20×150 mm dishes until 80–90%
confluent. For one 150 mm dish, 25 μg pHelper (Stratagene, La
Jolla, CA, USA), 18 μg of pdsAAVGFP or pdsAAVΔGFP, and
7 μg of rep/cap plasmid which varies with serotype (see above)
were added to 2 ml of 0.25 M CaCl2. The solution was gently
vortexed while a 2× buffer (280 mM NaCl, 50 mM HEPES and
1.5 mM Na2HPO4) was slowly dripped into the solution. After
15–17 h, transfection media were replaced with 293 media. Forty
eight hours post-transfection, the cells and media were harvested
and centrifuged for 5 min at 800 ×g, 4 °C. The pellet was
resuspended in 1 ml of 50 mM Tris–HCl pH 8.0, 150 mM NaCl,
2 mMMgCl2 (resuspension buffer) per 150 mm dish. The resus-
pended cells were frozen and stored at −80 °C until purification.
AAV purification and titering
All serotypes of AAV vectors were purified by CsCl ultra-
centrifugation based on established methods (Xiao et al., 1998)
with modifications. Cell pellets were freeze–thawed 3 times,
vortexing after each thaw. Benzonase was then added (50 units/
ml of cell solution; Sigma-Aldrich) for 1 h at 37 °C with
occasional mixing. Cell debris was centrifuged for 20 min at
2450 ×g, 4 °C. Supernatant was adjusted to 30 ml using resus-
pension buffer followed by 10 ml 2.5 M NaCl and 10 ml 40%
PEG 8000 and incubated at 4 °C for 18–20 h. The solution was
centrifuged for 20 min at 2450 ×g, 4 °C and the pellet was
resuspended in 20 ml of 50 mMHEPES, 150 mMNaCl, 20 mM
EDTA, pH 8.0 and 1% Sarcosyl. The solution was transferred to
36 ml ultracentrifuge tube and under laid consecutively with
1.3 g/ml and 1.5 g/ml CsCl in PBS. The CsCl interfaces were
marked and mineral oil was used for balancing. The tubes werecentrifuged (Discovery 100SE; Sorvall, Newton, CT) in a
Surespin 630/36 rotor (Sorvall) at 166,900 ×g 10 °C for 20–24 h.
Approximately 8 ml was removed using an 18 g needle inserted
2 mm below the 1.5–1.3 g/ml CsCl interface. The solution was
transferred to a 17 ml ultracentrifuge tube, under laid with 2 ml
of 1.5 g/ml CsCl, balanced and centrifuged for 24–48 h at
110,000 ×g, 10 °C. Fractions were collected via an 18 g needle
inserted below the 1.5 g/ml interface. Using the refractive index,
fractions with a Brix % between 21.0 and 28.0% were pooled
and dialyzed using a 10,000 MWCO dialysis cassette (Pierce,
Rockford, IL, USA) PBS containing 0.5 mM MgCl2 with three
exchanges over 25–30 h. The equilibrated virus was aliquoted,
frozen, and stored at −80 °C. Viral titers were determined using
Real-time quantitative PCR with “TaqMan™” chemistry and
analyzed by Opticon2 thermalcycler (Biorad, Hercules, CA,
USA). Titers were calculated as viral genomes based on a stan-
dard curve of pdsAAVGFP plasmid linearized with MluI. The
concentration of the linearized plasmid was determined using
a ND-1000 spectrophotometer (Nanodrop, Wilminton, DE,
USA) and visually checked on agarose gel containing a Low
Mass DNA ladder (Invitrogen). The linearized plasmid was
diluted in PBS to obtain concentrations ranging from 1×10−1 to
10−5 vg/ml equivalents. A viral aliquot was thawed, sonicated
for 10 s and serially diluted from 1:1000 to 1:10,000 in PBS.
Standards and 10−3 and 10−4 dilutions (triplicates) were assayed
using Taqman Master mix (Applied Biosystems, Foster City,
CA, USA) with eGFP primers and probe (Biosearch Technol-
ogies, Inc. Novato, CA, USA) under the following reaction
conditions: 95 °C, 5 min; 94 °C, 20 s and 60 °C, 1 min, 41 times.
Primer and probe sequences: 5′ AGCAAAGACCCCAACG
AGAA 3′(fwd), 5′ FAM-CGCGATCACAT GGTCCTGCTGG-
BH1 3′ (probe), and 5′GGCGGCGGTCACGAACT'3′(rev).
AAV transduction of primary cortical cultures
Cultures were transduced on DIV6 using each rAAV serotype
normalized to 2×1012 vg/ml and serially diluted in the PBS
containing 0.5 mMMgCl to obtain 2×1011, 2×1010, and 2×109
viral genomes (vg)/ml. Five microliters of media was added to
each well of a 96 well plate containing approximately 50,000
cells in 100 μl. Plates were gently mixed and returned to 37 °C
incubator for 2 h followed by a replacement of 100 μl of fresh
feed media. For cultures harvested at DIV12, cells were fed by
50% media exchange on DIV8 and DIV11 using feed media.
LDH and MTS assays
For LDH assay, media were collected from DIV8 cultures
and assayed using the Cytotoxicity Detection Kit (LDH; Roche
Applied Sciences, Indianapolis, IN, USA) according to manu-
facturer's recommendations (Koh and Choi, 1987). For MTS
assay, 100 μl of media was removed from each well on DIV8
for LDH then 20 μl of MTS reagent from the CellTiter 96
AQueous One Solution cell proliferation assay (Promega,
Madison, WI) was added to each well. Plates were returned to
the 37 °C incubator for 1 h then the A490 nm was read using a
Biotek ELx 808iu spectrophotometer (BioTek Instruments).
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At indicated time (DIV8 or DIV12), cells were fixed in 200 μl
of 4% paraformaldehyde in PBS for 1 h at room temperature,
washed and stored in PBS at 4 °C. For immunofluorescent labeling
cells were permeabilized 15 min in room temperature in PBS
containing 0.1% Triton X-100 (Sigma) and 0.2% bovine serum
albumin (BSA; Sigma). Cells were incubated in PBS containing
0.1% Triton X-100, 2% BSA, and 5% goat serum (Sigma) for 1 h.
Primary antibodies to GFAP (mouse anti-GFAP; #MAB360;
Millipore, Billerica,MA) orNeuN (mouse anti-NeuN; #MAB377;
Millipore) were diluted 1:500, and/or GFP (chicken anti-GFP;
AB16901; Millipore) was diluted 1:5000 in PBS containing 0.1%
Triton X-100 and 5% goat serum. Cells were incubated in primary
antibodies overnight at 4 °C with gentle shaking. After 3×5 min
washes in PBS, secondary antibodies (Alexa fluor 568 goat anti-
mouse and/or Alexa fluor 488 goat anti-chicken; Invitrogen) were
diluted 1:500 in PBS containing 0.1% Triton X-100 and 5% goat
serum and added to cells for 1 h at room temperature. After
2×5 min washes in PBS, 0.001% DAPI (Invitrogen) in PBS was
added 10 min at room temperature. Cells were washed 2×5 min
and stored away from light at 4 °C until imaging.
Immunolabelled cells were imaged with a Nikon Eclipse
TE2000-E inverted microscope (Nikon, Melville, NY) using a
Spot RT slider camera (Diagnostic Instruments, Sterling Heights,
MI) and MetaMorph v6.2 software (Molecular Devices,
Sunnyvale, CA). Briefly, the microscope stage was programmed
to move to the center of each well for manual focusing. Once
focused, the stage moved to 4 locations per well and acquired
images using UV filter (DAPI), FITC filter (GFP and Alexa 488)
and rhodamine (Alexa 568). Exposure times were kept constant
for each filter. Immunoreactive pixel densities (GFAP) or cell
counts (NeuN or DAPI) were made using the integrated
morphometry feature of Metamorph.
Phylogenetic analysis of AAV capsid-encoding genes
A phylogenetic tree was generated using Discovery Studio
Gene v1.5 (Accelyrs, San Diego, CA) by first aligning with Clus-
talWanalysis of the translated capsid region of AAV1 (Accession#
AF063497, nts2223-4433), AAV2 (AF043303, nts2203-4410),
AAV5 (AF085716, nts2207-4381), AAV6 (AF028704, nts 2208-
4418), AAV7 (AF513851, nts 2122-4435), AAV8 (AF513852, nts
2121-4437) and AAV9 (AY530629). Phylogenetic reconstruction
of the AAV capsids was generated using neighbor-joining method
in best tree mode with distances calculated as uncorrected “p”with
gaps distributed proportionally. The resulting phylogenetic treewas
rooted to AAV2.
Statistics
All experiments were conducted independently 3–6 times
using n=6–18 wells (MTS and LDH) or 2 times using n=3–9
wells (immunolabeling). Statistical analyses were performed
with One-way ANOVA and either post-hoc Student–Newman–
Keuls test or Dunnett's. Significance was inferred at pb0.05.
Data are presented as mean+/−S.E.M.Acknowledgment
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